Energy Storage Company Fluence Launches with Unparalleled Suite of Capabilities for Customers in Over 160 Countries
Fluence Energy, LLC (“Fluence”), an energy storage technology and services company jointly owned by Siemens and The AES Corporation (“AES”), announced the receipt of all government approvals and authorizations and the launch of business operations on January 1, 2018. Fluence combines the engineering, product development, implementation and services capabilities of AES Energy Storage and Siemens’ energy storage team and embarks on an aggressive expansion of the business backed by the financial support of the two parent organizations.
Fluence is also announcing that it will be the supplier of the world’s largest lithium-ion battery-based storage project, a 100 MW/400 MWh (4-hour duration) installation in Long Beach, California serving Southern California Edison and the Western Los Angeles area. Bringing together the people, technology and customers of AES Energy Storage and Siemens’ energy storage team, Fluence builds on more than a decade of grid-scale battery-based energy storage experience and the largest advanced battery-based energy storage fleet in the world with nearly 500 MW deployed or awarded across 15 countries.
Finally, Fluence is announcing a new and ongoing sales partnership through which the Siemens global sales force will market and sell Fluence energy storage systems, including Siestorage, Advancion, and the newest Fluence platform, SunFlex Energy Storage for solar PV. This new partnership provides Fluence with a global sales presence in 160 countries from a trusted supplier to thousands of utilities, power developers and large commercial customers, while giving Siemens access to the most proven and widely deployed grid storage technology platforms.
“We continue to believe in and deliver on the promise of energy storage to reduce costs, improve power systems, and create a more sustainable future,” said Stephen Coughlin, president and CEO of Fluence. “However, we saw customers struggling to find a trusted technology partner with deep knowledge of the power sector and the ability to deliver an industrial grade solution they could count on to be there in the future. With a team drawn from both Siemens and AES, we are fluent in the power sector and bring the capabilities, global reach and experience to make sure our customers achieve the full value of storage.”
The market for energy storage is accelerating with Bloomberg New Energy Finance projecting it to reach $100 billion by 2030. Utilities, developers and large energy users worldwide recognize energy storage’s value as critical infrastructure that provides greater reliability, resilience and efficiency. These customers are calling for industrial-grade solutions, power sector expertise and financial stability not available from technology startups, battery manufacturers, automakers or others. Fluence was designed to answer those needs, a company custom-built to deliver the most comprehensive set of energy storage solutions and services globally, including:
- Bankable, proven and industrial-strength technology platforms optimized for different customer needs, including speed of response, long-term dependability and integration with other power resources;
- A comprehensive set of services and warranties covering the entire energy storage journey, from early-stage commercial analytics through the full operations and maintenance life-cycle of a project;
- The broadest set of energy storage grid applications including power generation, transmission and distribution alternatives, renewable energy integration, and commercial and industrial applications;
- Full turn-key installation and support services in more than 160 countries, tailored to meet specific needs and conditions; and
- A suite of financing packages through a new partnership with Siemens Financial Services, including leasing and project finance options.
“Throughout 2017, the energy storage industry has seen several mergers and acquisitions, as well as a large number of partnership agreements,” said Sam Wilkinson, senior research manager at IHS Markit, a global business information provider. “We have entered a growth phase in the industry and the companies best positioned for success will require a proven track record, technology expertise, a global service network, and an ability to serve a broad set of energy storage applications.”
Fluence brings that breadth of experience and capabilities to serve both AES Energy Storage and Siemens’ existing projects and new projects for customers around the globe. The 100 MW/400 MWh Alamitos energy storage contract adds to the set of projects Fluence will support (directly or indirectly), including:
- 40 MW of new 4-hour storage and 37.5 MW of existing 4-hour storage for San Diego Gas & Electric, including the largest lithium-ion battery energy storage installation in North America, providing key capacity for reliability in southern California;
- A microgrid project for Italian energy utility Enel on the Mediterranean island of Ventotene, where battery storage is helping reduce fuel use, costs and emissions on the island’s network;
- Three projects adding much needed reliability for Arizona Public Service’s distribution grid in areas with high solar penetration – including one that will take the place of rebuilding about 20 miles of transmission and distribution poles and wires;
- Six energy storage projects being installed across Germany, providing key frequency regulation (primary control resource) services for grid stabilization; and
- Two 10 MW projects in the Dominican Republic for AES Dominicana that added critical resilience for the island’s grid during last September’s hurricanes.
With 10 years of experience deploying energy storage solutions, Fluence’s team focuses on solving customers’ energy problems, prioritizing lasting partnerships over simply delivering products. Fluence will deliver the same level of excellence in service, problem solving and delivery that customers know and depend on from working with us as AES Energy Storage or Siemens.
Learn more about Fluence, its team, and its new technology and service offerings at http://fluenceenergy.com.
Fluence, a Siemens and AES company, is a global energy storage technology solutions and services company that combines the agility of a technology company with the expertise, vision, and financial backing of two industry powerhouses. Established in 2018, as the successor to industry pioneers AES Energy Storage and Siemens energy storage, Fluence’s goal is to create a more sustainable future by transforming the way we power our world. The company offers proven energy storage technology solutions designed to address the diverse needs and challenges of customers in a rapidly transforming energy landscape, providing design, delivery and integration in over 160 countries. Fluence works closely with customers during every step of their journey and provides advisory, financing, and project lifecycle services. To date, Fluence’s teams have deployed or been awarded a market-leading 56 projects with a total capacity of 485 MW in 15 countries. To learn more, please visit http://fluenceenergy.com/ and follow Fluence on Twitter at @FluenceEnergy.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an